Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Status:
Active, not recruiting
Trial end date:
2024-04-24
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects of sitravatinib and how well it works with
nivolumab in treating patients with kidney cancer that has spread to other places in the
body. Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Giving sitravatinib and nivolumab may work better in treating patients with
kidney cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Mirati Therapeutics Inc. National Cancer Institute (NCI)